8月19日，伟思医疗今日收盘57.5元，上涨3.08%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到48.55倍，创385天以来新低，总市值55.07亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入9591.27万元，同比9.40%；净利润3322.01万 元，同比52.71%，销售毛利率66.65%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13伟思医疗48.5554.013.3155.07亿行业平均 59.4955.005.10121.17亿行业中值40.1939.642.9559.18亿1九安医疗11.6511.780.92196.54亿2英科医疗 15.3616.561.37242.73亿3新华医疗16.2915.101.33104.41亿4山东药玻16.3516.401.88154.62亿5奥美医疗 17.0016.661.7561.43亿6振德医疗17.7516.731.1364.43亿7九强生物17.8516.602.1988.42亿8康德莱 18.4018.421.5339.66亿9奥泰生物18.5619.571.5059.18亿10维力医疗18.57 ...

8月15日，伟思医疗今日收盘55.51元，上涨1.82%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到46.87倍，总市值53.16亿元。 南京伟思医疗科技股份有限公司的主营业务是医疗器械的研发、生产和销售。公司的主要产品是磁刺激 类、电刺激类、电生理类、耗材及配件、激光射频类。 最新一期业绩显示，2025年一季报，公司实现营业收入9591.27万元，同比9.40%；净利润3322.01万 元，同比52.71%，销售毛利率66.65%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13伟思医疗46.8752.143.2053.16亿行业平均 56.5852.305.00119.53亿行业中值39.9739.072.9157.03亿1九安医疗11.3611.490.89191.70亿2英科医疗 15.6416.861.39247.04亿3山东药玻16.2816.331.87154.02亿4新华医疗16.6315.411.36106.59亿5奥美医疗 17.1216.781.7661.87亿6振德医疗17.3816.381.1163.10亿7九强生物17.7016.462.1787.65 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Weisi Medical, which closed at 54.52 yuan with a decline of 2.64%, resulting in a rolling PE ratio of 46.03 times and a total market value of 5.221 billion yuan [1] - In comparison to the medical device industry, Weisi Medical's PE ratio is below the industry average of 55.76 times and the industry median of 39.14 times, ranking 82nd in the sector [1][2] - As of the first quarter of 2025, only one institution holds shares in Weisi Medical, with a total of 90,000 shares valued at 0.04 million yuan [1] Group 2 - Weisi Medical specializes in the research, production, and sales of medical devices, with key products including magnetic stimulation, electrical stimulation, electrophysiology, consumables and accessories, and laser radiofrequency [1] - The latest financial results for the first quarter of 2025 show that the company achieved a revenue of 95.9127 million yuan, representing a year-on-year increase of 9.40%, and a net profit of 33.2201 million yuan, reflecting a year-on-year growth of 52.71%, with a gross profit margin of 66.65% [1]

来源：金融界 股东方面，截至2025年3月31日，伟思医疗股东户数5933户，较上次增加637户，户均持股市值35.28万 元，户均持股数量2.76万股。 南京伟思医疗科技股份有限公司的主营业务是医疗器械的研发、生产和销售。公司的主要产品是磁刺激 类、电刺激类、电生理类、耗材及配件、激光射频类。 最新一期业绩显示，2025年一季报，公司实现营业收入9591.27万元，同比9.40%；净利润3322.01万 元，同比52.71%，销售毛利率66.65%。 8月1日，伟思医疗今日收盘45.5元，下跌1.60%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到38.41倍，总市值43.58亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均53.65倍，行业中值37.22倍，伟思医疗排 名第79位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13伟思医疗38.4142.732.6243.58亿行业平均 53.6550.024.68114.74亿行业中值37.2237.112.6755.30亿1九安医疗11.0111.130.87185.78亿2英科医疗 15.4516.651.37 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Weisi Medical, which closed at 44.14 yuan, down 6.18%, with a rolling PE ratio of 37.27 times and a total market capitalization of 4.227 billion yuan [1][2] - The average PE ratio for the medical device industry is 53.52 times, with a median of 37.14 times, placing Weisi Medical at the 76th position in the industry ranking [1][2] - As of March 31, 2025, Weisi Medical has 5,933 shareholders, an increase of 637 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Weisi Medical specializes in the research, production, and sales of medical devices, with key products including magnetic stimulation, electrical stimulation, electrophysiology, consumables and accessories, and laser radiofrequency [1] - In the latest quarterly report for Q1 2025, the company achieved a revenue of 95.9127 million yuan, a year-on-year increase of 9.40%, and a net profit of 33.2201 million yuan, reflecting a year-on-year growth of 52.71%, with a gross profit margin of 66.65% [1]

Company Overview - Weisi Medical's closing price on July 9 was 45.03 yuan, down 1.27%, with a rolling PE ratio of 38.02 times and a total market value of 4.313 billion yuan [1] - The company ranks 80th in the medical device industry, which has an average PE ratio of 51.36 times and a median of 37.22 times [1] Financial Performance - For the first quarter of 2025, Weisi Medical reported revenue of 95.9127 million yuan, a year-on-year increase of 9.40% [1] - The net profit for the same period was 33.2201 million yuan, reflecting a year-on-year growth of 52.71% [1] - The sales gross margin stood at 66.65% [1] Shareholding Structure - As of the first quarter of 2025, five institutions held shares in Weisi Medical, including three other entities and two funds, with a total holding of 10.7452 million shares valued at 364 million yuan [1]

Company Overview - Weisi Medical's closing price on July 1 was 47.9 yuan, reflecting a 3.03% increase, with a rolling PE ratio of 40.44, marking a 16-day low, and a total market capitalization of 4.587 billion yuan [1] - The company specializes in the research, production, and sales of medical devices, with key products including magnetic stimulation, electrical stimulation, electrophysiology, consumables and accessories, and laser radiofrequency [1] Financial Performance - In the first quarter of 2025, Weisi Medical reported revenue of 95.9127 million yuan, representing a year-on-year increase of 9.40%, and a net profit of 33.2201 million yuan, up 52.71%, with a gross profit margin of 66.65% [1] Shareholder Information - As of March 31, 2025, Weisi Medical had 5,933 shareholders, an increase of 637 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] Industry Comparison - The average PE ratio for the medical device industry is 51.70, with a median of 37.36, placing Weisi Medical at the 81st position within the industry [1][2] - The static PE ratio for Weisi Medical is 44.99, and the price-to-book ratio is 2.76 [2]